Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study
Lancet Rheumatol. 2022. Epub ahead of print. doi: 10.1016/S2665-9913(22)00304-6
Treat-to-target goals for patients with SLE have been validated to protect against organ damage and to improve quality of life. With this in mind, Kandane-Rathnayake, et al. used data from patients with SLE in the Asia Pacific Lupus Collaboration cohort to test the hypothesis that LLDAS has a protective association with mortality risk.